Guidelines for ketamine use in clinical psychiatry practice.

IF 3.9 3区医学 Q1 PSYCHIATRY

BJPsych Open Pub Date : 2024-05-10 DOI:10.1192/bjo.2024.62

Luke A Jelen, Rupert McShane, Allan H Young

引用次数: 0

Abstract

In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to monitor ketamine therapy, ensuring its responsible and effective use in the management of depression.

查看原文本刊更多论文

在临床精神病学实践中使用氯胺酮的指南。

在这篇社论中，我们强调了使用氯胺酮治疗耐药抑郁症的疗效和挑战。我们强调有必要制定以证据为基础的综合指南，以管理许可和非许可氯胺酮制剂的使用，并讨论了 Beaglehole 等人最近为制定新西兰氯胺酮指南所做的努力。最后，我们主张建立国家登记册，对氯胺酮疗法进行监测，确保其在抑郁症治疗中得到负责任和有效的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJPsych Open Medicine-Psychiatry and Mental Health

CiteScore

6.30

自引率

3.70%

发文量

610

审稿时长

16 weeks

期刊介绍： Announcing the launch of BJPsych Open, an exciting new open access online journal for the publication of all methodologically sound research in all fields of psychiatry and disciplines related to mental health. BJPsych Open will maintain the highest scientific, peer review, and ethical standards of the BJPsych, ensure rapid publication for authors whilst sharing research with no cost to the reader in the spirit of maximising dissemination and public engagement. Cascade submission from BJPsych to BJPsych Open is a new option for authors whose first priority is rapid online publication with the prestigious BJPsych brand. Authors will also retain copyright to their works under a creative commons license.